SOPH Stock Analysis: Buy, Sell, or Hold?
SOPH - SOPHiA GENETICS SA Ordinary Shares
$5.09
0.14 (2.83%)
▲
5d:
+7.84%
30d:
+24.15%
90d:
+7.61%
BUY
MODERATE Confidence
Analysis Updated: Apr 1, 2026 12:00 AM ET
Earnings: May 05, 2026
Smart Money Accumulation
SOPH is down 5.4% this week, but smart money is accumulating calls. Top strike: $5 2026-03-20 with 1,292 OI. Call ratio: 100% View Scanner →
Strength: 7.7/10
Get Alerted When SOPH Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: SOPH shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: SOPH shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: SOPH is currently trading at $5.09, which is considered extended relative to its 30-day fair value range of $4.41 to $4.93.
Technical Outlook: Technically, SOPH is showing sideways momentum. Immediate support is located at $4.55, while resistance sits at $5.35.
Market Sentiment: SOPH has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $7.67 (+50.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, SOPH is showing sideways momentum. Immediate support is located at $4.55, while resistance sits at $5.35.
Market Sentiment: SOPH has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $7.67 (+50.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Fair Price Range
$4.41 -
$4.93
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
70.8%
All Signals
- BEARISH: Price extended above range
- BULLISH: Options cheap (IV 0th percentile)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 50.6% below Wall St target ($7.67)
Fair Price Analysis
30-Day Fair Range
$4.41 -
$4.93
Current vs Fair Value
EXTENDED
Expected Move (7 Days)
±$0.48
(9.5%)
Support & Resistance Levels
Support Level
$4.55
Resistance Level
$5.35
Current Trend
Sideways
Technical data as of
Apr 1, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-9.09
Wall Street Target
$7.67
(+50.6%)
Revenue Growth (YoY)
22.4%
Profit Margin
-102.2%
Share & Embed Analysis
Last updated: April 02, 2026 7:39 AM ET
Data refreshes hourly during market hours. Next update: 8:39 AM
Data refreshes hourly during market hours. Next update: 8:39 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SOPH showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Health Information Services Stocks
Top-rated stocks in Health Information Services by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
VEEV
Veeva Systems Inc Class A |
BUY
32 analysts |
$271 | 54 HOLD |
|
PRVA
Privia Health Group Inc |
STRONG BUY
21 analysts |
$32 | 61 BUY |
|
GEHC
GE HealthCare Technologi… |
STRONG BUY
21 analysts |
$90 | 65 BUY |
|
HQY
HealthEquity Inc |
STRONG BUY
14 analysts |
$112 | 66 BUY |
|
PHR
Phreesia Inc |
STRONG BUY
15 analysts |
$28 | 53 HOLD |
